uniQure N.V. (QURE)

Price$18.04

Favorite Metrics

Price vs S&P 500 (26W)-77.80%

Price vs S&P 500 (4W)5.18%

Market Capitalization$1.07B

All Metrics

Book Value / Share (Quarterly)$3.19

P/TBV (Annual)11.69x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-46.73%

Cash Flow / Share (Quarterly)$-2.86

Price vs S&P 500 (YTD)-28.54%

Gross Margin (TTM)89.53%

Net Profit Margin (TTM)-1236.00%

EPS (TTM)$-3.48

10-Day Avg Trading Volume1.71M

EPS Excl Extra (TTM)$-3.48

Revenue Growth (5Y)-15.56%

EPS (Annual)$-3.46

ROI (Annual)-27.57%

Gross Margin (Annual)89.53%

Net Profit Margin (5Y Avg)-824.52%

Cash / Share (Quarterly)$9.99

Revenue Growth QoQ (YoY)6.65%

ROA (Last FY)-24.12%

Revenue Growth TTM (YoY)-40.64%

EBITD / Share (TTM)$-2.79

ROE (5Y Avg)-54.23%

Operating Margin (TTM)-1151.38%

Cash Flow / Share (Annual)$-2.86

P/B Ratio5.39x

P/B Ratio (Quarterly)7.41x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)94.10x

Net Interest Coverage (TTM)-9.23x

ROA (TTM)-27.41%

EV / EBITDA (TTM)4.90x

EPS Incl Extra (Annual)$-3.46

Current Ratio (Annual)10.43x

Quick Ratio (Quarterly)10.10x

3-Month Avg Trading Volume2.97M

52-Week Price Return38.77%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.02

P/S Ratio (Annual)66.61x

Asset Turnover (Annual)0.02x

52-Week High$71.50

Operating Margin (5Y Avg)-738.32%

EPS Excl Extra (Annual)$-3.46

CapEx CAGR (5Y)-45.93%

Tangible BV CAGR (5Y)-16.87%

26-Week Price Return-70.91%

Quick Ratio (Annual)10.10x

13-Week Price Return-17.93%

Total Debt / Equity (Annual)2.63x

Current Ratio (Quarterly)10.43x

Enterprise Value$1,514.872

Revenue / Share Growth (5Y)-19.78%

Asset Turnover (TTM)0.02x

Book Value / Share Growth (5Y)-15.47%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)3.05x

Pretax Margin (Annual)-1201.02%

Cash / Share (Annual)$9.99

3-Month Return Std Dev156.66%

Gross Margin (5Y Avg)65.59%

Net Income / Employee (TTM)$-1

ROE (Last FY)-100.04%

Net Interest Coverage (Annual)-5.13x

EPS Basic Excl Extra (Annual)$-3.46

P/FCF (TTM)28.83x

Receivables Turnover (TTM)2.74x

Total Debt / Equity (Quarterly)2.63x

EPS Incl Extra (TTM)$-3.48

Receivables Turnover (Annual)2.74x

ROI (TTM)-24.19%

P/S Ratio (TTM)66.61x

Pretax Margin (5Y Avg)-813.47%

Revenue / Share (Annual)$0.28

Tangible BV / Share (Annual)$2.02

Price vs S&P 500 (52W)4.14%

Year-to-Date Return-24.61%

5-Day Price Return5.56%

EPS Normalized (Annual)$-3.46

ROA (5Y Avg)-16.30%

Net Profit Margin (Annual)-1236.00%

Month-to-Date Return10.34%

Cash Flow / Share (TTM)$-4.60

EBITD / Share (Annual)$-2.78

Operating Margin (Annual)-1151.38%

LT Debt / Equity (Annual)2.63x

ROI (5Y Avg)-18.15%

LT Debt / Equity (Quarterly)2.63x

EPS Basic Excl Extra (TTM)$-3.48

P/TBV (Quarterly)11.69x

P/B Ratio (Annual)7.41x

Inventory Turnover (TTM)3.05x

Pretax Margin (TTM)-1201.02%

Book Value / Share (Annual)$3.19

Price vs S&P 500 (13W)-20.31%

Beta0.73x

P/FCF (Annual)3.96x

Revenue / Share (TTM)$0.26

ROE (TTM)-104.86%

52-Week Low$8.73

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.15

4.05

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
QUREuniQure N.V.	66.61x	-40.64%	89.53%	—	$18.04
LLYEli Lilly & Co.	13.45x	44.70%	83.04%	27.59%	$919.90
JNJJohnson & Johnson	5.82x	7.87%	67.95%	14.90%	$230.69
ABBVABBVIE INC.	5.97x	8.57%	71.62%	-2.88%	$203.71
MRKMerck & Co., Inc.	4.51x	1.31%	78.55%	21.23%	$117.10
AZNAstraZeneca PLC	5.39x	8.63%	81.31%	21.88%	$200.69
NVSNovartis AG	4.87x	8.91%	75.82%	15.26%	$150.99
NVONovo-Nordisk A/S	3.74x	6.43%	80.98%	20.66%	$40.46
ABTAbbott Laboratories	3.71x	6.59%	56.50%	8.20%	$96.00
PFEPfizer Inc.	2.50x	-1.64%	75.81%	-3.51%	$27.52
BMYBristol-Myers Squibb Co.	2.52x	-0.22%	72.63%	—	$59.13

About

uniQure NV is a gene therapy company developing treatments for hemophilia, Huntington's disease, and cardiovascular diseases. The company has established a collaboration with Bristol Myers Squibb to advance its cardiovascular gene therapy pipeline.